NVX-CoV2373 COVID vaccine safe and effective in preventing COVID-19 in adolescent

United Kingdom News News

NVX-CoV2373 COVID vaccine safe and effective in preventing COVID-19 in adolescent
United Kingdom Latest News,United Kingdom Headlines
  • 📰 NewsMedical
  • ⏱ Reading Time:
  • 72 sec. here
  • 3 min. at publisher
  • 📊 Quality Score:
  • News: 32%
  • Publisher: 71%

NVX-CoV2373 COVID vaccine safe and effective in preventing COVID-19 in adolescent Vaccine Coronavirus Disease COVID19 NVXCoV2373 Adolescents Phase3trial Prevention Novavax ClinicalTrial JAMANetworkOpen

By Pooja Toshniwal PahariaApr 27 2023 In a recent study published in JAMA Network Open, researchers evaluated the efficacy, immunogenicity, and safety of Novavax’s NVX-CoV2373 vaccine in preventing coronavirus disease 2019 among 12-to 17-year-old adolescents.

The PREVENT-19 phase 3 trial findings demonstrated that the recombinant SARS-CoV-2 spike protein-encoding and Matrix-M-adjuvanted NVX-CoV2373 vaccine was effective and safe among adults in preventing symptomatic SARS-CoV-2 infections. Following the results, the trial was expanded to include vaccine assessments among adolescents.

A total of 57 adolescents with immunosuppressive conditions or prior COVID-19 history were excluded from the analysis. Therefore, out of 2,304 adolescents screened initially, 2,247 were 2:1 randomized to receive either two 0.50 mL intramuscular NVX-CoV2373 vaccine injections or placebo , 3.0 weeks apart.

In addition, serological human angiotensin-converting enzyme-2 -binding inhibition antibody titers and anti-S protein immunoglobulin G titers were determined using enzyme-linked immunosorbent assays . Further, a post hoc analysis was performed by measuring humoral responses against SARS-CoV-2 variants of concern , such as the Alpha VOC, Beta VOC, Gamma VOC, Delta VOC, and Omicron VOC, and variants of interest such as the Mu VOI.

Within 64 days of the follow-up period, 20 cases of mild COVID-19 were reported, including six cases in the NVX-CoV2373 vaccine recipient group and 14 cases in the placebo group. The incidence rates among NVX-CoV2373 vaccinees and placebo recipients were 2.9 and 14, respectively, yielding a 79.50% efficacy for NVX-CoV2373.

We have summarized this news so that you can read it quickly. If you are interested in the news, you can read the full text here. Read more:

NewsMedical /  🏆 19. in UK

United Kingdom Latest News, United Kingdom Headlines

Similar News:You can also read news stories similar to this one that we have collected from other news sources.

NIST looks to establish network of US research fabsNIST looks to establish network of US research fabsHands off, vendors – it's for research! $11B of US CHIPs funds earmarked for NIST fabs
Read more »

Research identifies Th1 memory CD4+ T cells as key to protect against emerging poxvirus skin infectionsResearch identifies Th1 memory CD4+ T cells as key to protect against emerging poxvirus skin infectionsResearch identifies Th1 memory CD4+ T cells as key to protect against emerging poxvirus skin infections CellReports OHSUNews mpox poxvirus pox cirus viral skin infection skininfection emerging publichealth virology microbiology molecular
Read more »

University of Edinburgh to review links to slavery and colonialismUniversity of Edinburgh to review links to slavery and colonialismUniversity of Edinburgh to review links to slavery and colonialism by LeahMahon_
Read more »

AI creators must study consciousness, experts warnAI creators must study consciousness, experts warnAn open letter calls on the technology sector to research consciousness, as AI becomes more advanced.
Read more »

Exclusive: Vulnerable People 'Abandoned' As Energy Bill Help Falls Hundreds Of Pounds ShortExclusive: Vulnerable People 'Abandoned' As Energy Bill Help Falls Hundreds Of Pounds ShortNew research reveals millions of people will be hit by increased costs.
Read more »



Render Time: 2025-02-16 07:19:57